Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Oil & Gas, Telecoms and Basic Materials sectors led shares higher. At the close in NYSE, the...
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Technology, Oil & Gas and Telecoms sectors led shares higher. At the close in NYSE, the Dow...
Galmed Pharma (GLMD) reported Q4 EPS of ($0.30), in-line with the analyst estimate of ($0.30).
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was a big mover last session, as the company saw its shares rise more than 8% on the day. The move came on solid volume too with far...
The promising but challenging indication of nonalcoholic steatohepatitis (NASH) hit headlines following two major developments.Firstly, the frontrunner in the NASH space, Intercept...
Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) have gained 59.2% in the year so far, against the industry’s decline of 25.6%. Intercept’s focus is on...
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 60.25 | 60.87 | 59.36 | +0.32 | +0.53% | 1.09M | NYSE | |||
| 15.98 | 15.99 | 15.96 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 4.94 | 5.04 | 4.66 | +0.300 | +6.47% | 1.03M | NYSE | |||
| 48.30 | 48.37 | 42.01 | +6.37 | +15.19% | 31.70M | NASDAQ | |||
| 70.80 | 70.81 | 69.99 | +0.69 | +0.98% | 1.20M | NYSE | |||
| 11.00 | 11.00 | 10.86 | +0.20 | +1.85% | 3.11M | NYSE | |||
| 5.38 | 5.43 | 5.15 | +0.250 | +4.87% | 1.55M | NYSE | |||
| 8.26 | 8.27 | 7.84 | +0.410 | +5.22% | 740.29K | NYSE | |||
| 21.02 | 21.28 | 21.02 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 35.52 | 35.75 | 34.96 | 0.000 | 0.00% | 0.00 | NASDAQ | |||
| 48.28 | 48.30 | 47.52 | +0.70 | +1.47% | 645.77K | NASDAQ | |||
| 102.26 | 102.40 | 99.38 | +3.51 | +3.55% | 103.91M | NASDAQ | |||
| 365.91 | 366.08 | 356.35 | +10.30 | +2.90% | 498.57K | NYSE | |||
| 3.15 | 3.16 | 2.94 | +0.21 | +7.14% | 1.70M | NYSE | |||
| 0.42 | 0.44 | 0.37 | +0.04 | +11.57% | 5.59M | NASDAQ |